Search tips
Search criteria 


Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
BMC Cancer. 2012; 12: 71.
Published online Feb 17, 2012. doi:  10.1186/1471-2407-12-71
PMCID: PMC3305620
Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis
Zhigang Cui,#1 Zhihua Yin,#2,3 Xuelian Li,2,3 Wei Wu,2,3 Peng Guan,2,3 and Baosen Zhoucorresponding author2,3,4
1China Medical University, Shenyang 110001, PR China
2Department of Epidemiology, School of Public Health, China Medical University, Shenyang 110001, PR China
3Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang 110001, PR China
4Department of Epidemiology, Key Laboratory of Cancer Etiology and Intervention, China Medical University, University of Liaoning Province, No. 92, North Second Road, Heping District, Shenyang 110001, People's Republic of China
corresponding authorCorresponding author.
#Contributed equally.
Zhigang Cui: zgcui/at/; Zhihua Yin: zhyin/at/; Xuelian Li: zimu0124/at/; Wei Wu: wuwei/at/; Peng Guan: pguan/at/; Baosen Zhou: bszhou/at/
Received August 19, 2011; Accepted February 17, 2012.
X-ray repair cross-complementing group 1 (XRCC1) protein plays an important role in the repair of DNA damage and adducts. Single nucleotide polymorphisms (SNPs) of XRCC1 are suspected to have some relationship with response to chemotherapy and overall survival of lung cancer. This meta-analysis aimed to summarize published data on the association between the commonest SNPs of XRCC1 (Arg194Trp, C > T, rs1799782 and Arg399Gln, G > A, rs25487) and clinical outcome of lung cancer patients.
We retrieved the relevant articles from PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases. Studies were selected using specific inclusion and exclusion criteria. Primary outcomes included objective response (i.e., complete response + partial response vs. progressive disease + stable disease) and overall survival (OS). Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were estimated. All analyses were performed using the Stata software.
Twenty-two articles were included in the present analysis. XRCC1 Arg194Trp and Arg399Gln polymorphisms were significantly associated with response to treatment in lung cancer patients. Patients with C/T genotype, T/T genotype and minor variant T allele at Arg194Trp were more likely to respond to platinum-based chemotherapy compared with those with C/C genotype (C/T vs. C/C: OR, 2.54; 95%CI, 1.95-3.31; T/T vs. C/C: OR, 2.06; 95%CI, 1.39-3.06; C/T+T/T vs. C/C: OR, 2.42; 95% CI, 1.88-3.10). For XRCC1 Arg399Gln, G/A genotype, A/A genotype and minor variant A allele were associated with objective response in all patients (G/A vs. G/G: OR, 0.67; 95%CI, 0.50-0.90; A/A vs. G/G: OR, 0.43; 95%CI, 0.25-0.73; A/A+G/A vs. G/G: OR, 0.63; 95%CI, 0.49-0.83). Both G/A and A/A genotypes of XRCC1 Arg399Gln could influence overall survival of lung cancer patients (G/A vs. G/G: HR, 1.23; 95%CI, 1.06-1.44; A/A vs. G/G: HR, 2.03; 95%CI, 1.20-3.45). Interaction analysis suggested that compared with the patients carrying C/T+T/T genotype at XRCC1 194 and G/G genotype at XRCC1 399, the patients carrying 194 C/C and 399 G/A+A/A or 194 C/C and 399 G/G genotype showed much worse objective response.
Genetic polymorphisms in XRCC1 gene might be associated with overall survival and response to platinum-based chemotherapy in lung cancer patients.
Articles from BMC Cancer are provided here courtesy of
BioMed Central